|Bid||28.13 x 800|
|Ask||28.07 x 900|
|Day's Range||27.50 - 28.36|
|52 Week Range||9.70 - 28.36|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||31.62|
|Earnings Date||Feb 18, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.75|
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Joseph Belanoff became the CEO of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) in 1999, and we think it's a good...
In this article we will analyze whether Corcept Therapeutics Incorporated (NASDAQ:CORT) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]